Outlook Therapeutics Inc
For the period ended Sep 30, 2024. Filed Dec 27, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Dec 27, 2024
OTLK$0.46+5.2%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
| | | | | | | |
|---|---|---|---|---|---|---|
| · · Year ended September 30, | ||||||
| | 2024 | 2023 | ||||
| Operating expenses: | | | | | | |
| Research and development | | $41,763,047 | | $26,452,942 | ||
| General and administrative | | | 29,940,188 | | | 26,673,440 |
| Loss from operations | | | (71,703,235) | | | (53,126,382) |
| Loss on equity method investment | | | 100,742 | | | 10,998 |
| Interest income | | | (906,150) | | | (971,480) |
| Interest expense | | | 3,156,964 | | | 2,531,228 |
| Loss on extinguishment of debt | | | — | | | 577,659 |
| Change in fair value of promissory notes | | | 2,457,153 | | | 3,756,000 |
| Warrant related expenses (Note 9) | | | 37,490,012 | | | — |
| Change in fair value of warrant liability | | | (38,638,042) | | | (50,919) |
| Loss before income taxes | | | (75,363,914) | | | (58,979,868) |
| Income tax expense | | | 2,800 | | | 2,800 |
| Net loss | | $(75,366,714) | | $(58,982,668) | ||
| | | | | | | |
| Per share information: | | | | | | |
| Net loss per share of common stock, basic and diluted | | $(4.06) | | $(4.72) | ||
| Weighted average shares outstanding, basic and diluted | | | 18,548,813 | | | 12,508,817 |
See accompanying notes to consolidated financial statements
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.